Screening for chronic obstructive pulmonary disease evidence report and systematic review for the US preventive services task force

JAMA - Journal of the American Medical Association

Volumn 315, Issue 13, 2016, Pages 1378-1393

  Guirguis Blake, Janelle M ^a,b,d   Senger, Caitlyn A ^b,c   Webber, Elizabeth M ^b,c   Mularski, Richard A ^b,c   Whitlock, Evelyn P ^b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; SALBUTAMOL; TIOTROPIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

AGE DISTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COUGHING; DISEASE EXACERBATION; DYSPNEA; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING; SENSITIVITY AND SPECIFICITY; SMOKING HABIT; SPIROMETRY; SYSTEMATIC REVIEW; XEROSTOMIA; ADVERSE EFFECTS; ADVISORY COMMITTEE; AGE; AREA UNDER THE CURVE; ASYMPTOMATIC DISEASES; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; STANDARDS; UNITED STATES;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADVISORY COMMITTEES; AGE FACTORS; AREA UNDER CURVE; ASYMPTOMATIC DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; RESPIRATORY FUNCTION TESTS; ROC CURVE; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SMOKING; SMOKING CESSATION; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; TIOTROPIUM BROMIDE; UNITED STATES;

EID: 84962562656     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.2654     Document Type: Review

References (71)

1. Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD surveillance: United States, 1999-2011. Chest. 2013;144(1):284-305.
2. Kochanek KD, Murphy SL, Xu J, Arias E. Mortality in the United States, 2013. NCHS Data Brief. 2014; (178):1-8.
3. Chronic obstructive pulmonary disease (COPD) fact sheet. American Lung Association. http://www.lung.org/lung-disease/copd/resources /facts-figures/COPD-Fact-Sheet.html. Accessed March 9, 2016.
4. COPD data and statistics. Centers for Disease Control and Prevention. http://www.cdc.gov/copd /data.htm. Accessed March 9, 2016.
5. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2000;160(11):1683-1689.
6. Hooper R, Burney P, Vollmer WM, et al. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J. 2012;39(6):1343-1353.
7. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.org/guidelines -global-strategy-for-diagnosis-management.html. Accessed March 9, 2016.
8. Qaseem A, Wilt TJ, Weinberger SE, et al; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-191.
9. Chronic obstructive pulmonary disease in over 16s: NICE guidelines [CG101]. National Institute for Health and Care Excellence. https://www.nice.org .uk/guidance/cg101. Accessed March 9, 2016.
10. US Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;148(7):529-534.
11. Guirguis-Blake JM, Senger CA, Webber EM, et al. Screening for Chronic Obstructive Pulmonary Disease: A Systematic Evidence Review for the US Preventive Services Task Force: Evidence Synthesis No. 130. Rockville, MD: Agency for Healthcare Research and Quality; 2016. AHRQ Publication 14-05205-EF-1.
12. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1-W73.
13. Bouwmeester W, Zuithoff NP, Mallett S, et al. Reporting and methods in clinical prediction research: a systematic review. PLoS Med. 2012;9(5): 1-12.
14. Sichletidis L, Spyratos D, Papaioannou M, et al. A combination of the IPAG questionnaire and PiKo-6 flow meter is a valuable screening tool for COPD in the primary care setting. Prim Care Respir J. 2011;20(2):184-189.
15. Buffels J, Degryse J, Heyrman J, Decramer M; DIDASCO Study. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest. 2004;125(4): 1394-1399.
16. Tinkelman DG, Price D, Nordyke RJ, Halbert RJ. COPD screening efforts in primary care: what is the yield? Prim Care Respir J. 2007;16(1):41-48.
17. Frith P, Crockett A, Beilby J, et al. Simplified COPD screening: validation of the PiKo-6 in primary care. Prim Care Respir J. 2011;20(2):190-198.
18. US Preventive Services Task Force. US Preventive Services Task Force Procedure Manual. Rockville, MD: Agency for Healthcare Research and Quality; 2008. AHRQ Publication 08-05118-EF.
19. National Institute for Health and Clinical Excellence. The Guidelines Manual. London, United Kingdom: National Institute for Health and Clinical Excellence; 2006.
20. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
21. Whiting PF, Rutjes AW, Westwood ME, et al; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-536.
22. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
23. Miller MR, Crapo R, Hankinson J, et al; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005;26(1):153-161.
24. Stanley AJ, Hasan I, Crockett AJ, van Schayck OC, Zwar NA. Validation of the COPD Diagnostic Questionnaire in an Australian general practice cohort: a cross-sectional study. Prim Care Respir J. 2014;23(1):92-97.
25. Dirven JA, Tange HJ, Muris JW, van Haaren KM, Vink G, van Schayck OC. Early detection of COPD in general practice: implementation, workload and socioeconomic status: a mixed methods observational study. Prim Care Respir J. 2013;22(3): 338-343.
26. Kotz D, Nelemans P, van Schayck CP, Wesseling GJ. External validation of a COPD diagnostic questionnaire. Eur Respir J. 2008;31(2): 298-303.
27. Mintz ML, Yawn BP, Mannino DM, et al. Prevalence of airway obstruction assessed by Lung Function Questionnaire. Mayo Clin Proc. 2011;86(5): 375-381.
28. Tsukuya G, Matsumoto K, Fukuyama S, et al; Hisayama Pulmonary Physiology Study Group. Validation of a COPD screening questionnaire and establishment of diagnostic cut-points in a Japanese general population: the Hisayama study. Allergol Int. 2015;64(1):49-53.
29. Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983;39(1):207-215.
30. Price DB, Tinkelman DG, Nordyke RJ, Isonaka S, Halbert RJ; COPD Questionnaire Study Group. Scoring system and clinical application of COPD diagnostic questionnaires. Chest. 2006;129(6): 1531-1539.
31. Price DB, Tinkelman DG, Halbert RJ, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration. 2006;73(3):285-295.
32. Hanania NA, Mannino DM, Yawn BP, et al. Predicting risk of airflow obstruction in primary care: validation of the Lung Function Questionnaire (LFQ). Respir Med. 2010;104(8):1160-1170.
33. Yawn BP, Mapel DW, Mannino DM, et al; Lung Function Questionnaire Working Group. Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2010;5:1-10.
34. Martinez FJ, Raczek AE, Seifer FD, et al; COPD-PS Clinician Working Group. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD. 2008;5(2):85-95.
35. Yawn BP, Duvall K, Peabody J, et al. The impact of screening tools on diagnosis of chronic obstructive pulmonary disease in primary care. Am J Prev Med. 2014;47(5):563-575.
36. Thorn J, Tilling B, Lisspers K, Jörgensen L, Stenling A, Stratelis G. Improved prediction of COPD in at-risk patients using lung function pre-screening in primary care: a real-life study and cost-effectiveness analysis. Prim Care Respir J. 2012;21(2):159-166.
37. Jithoo A, Enright PL, Burney P, et al; BOLD Collaborative Research Group. Case-finding options for COPD: results from the Burden of Obstructive Lung Disease study. Eur Respir J. 2013;41(3):548-555.
38. Perez-Padilla R, Vollmer WM, Vázquez-García JC, Enright PL, Menezes AM, Buist AS; BOLD and PLATINO Study Groups. Can a normal peak expiratory flow exclude severe chronic obstructive pulmonary disease? Int J Tuberc Lung Dis. 2009;13 (3):387-393.
39. Kotz D, Wesseling G, Huibers MJ, van Schayck OC. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J. 2009;33(4):754-762.
40. McClure JB, Ludman EJ, Grothaus L, Pabiniak C, Richards J. Impact of a brief motivational smoking cessation intervention: the Get PHIT randomized controlled trial. Am J Prev Med. 2009; 37(2):116-123.
41. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008;336(7644):598-600.
42. Sippel JM, Osborne ML, Bjornson W, Goldberg B, Buist AS. Smoking cessation in primary care clinics. J Gen Intern Med. 1999;14(11):670-676.
43. Risser NL, Belcher DW. Adding spirometry, carbon monoxide, and pulmonary symptom results to smoking cessation counseling: a randomized trial. J Gen Intern Med. 1990;5(1):16-22.
44. Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med. 2013;107 (2):223-232.
45. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009; 10:59.
46. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171-1178.
47. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143(5): 317-326.
48. Tonnel AB, Perez T, Grosbois JM, Verkindre C, Bravo ML, Brun M; TIPHON study group. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(2):301-310.
49. Pauwels RA, Löfdahl CG, Laitinen LA, et al; European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 1999;340(25): 1948-1953.
50. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353(9167):1819-1823.
51. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009;151(8):517-527.
52. Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res. 2008;9:73.
53. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343(26):1902-1909.
54. Löfdahl CG, Postma DS, Pride NB, Boe J, Thorén A. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J. 2007;29(6):1115-1119.
55. Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med. 2014;24:14003.
56. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Mölken MR. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2010; 5:435-444.
57. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029-1036.
58. Calverley PM, Stockley RA, Seemungal TA, et al; Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2011;139(3):505-512.
59. Enright P. Patients are hurt by a false diagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(2):229.
60. Kaplan A, Freeman D, Cleland J, Cerasoli F, Price D. Detecting mild COPD is not a waste of resources. Prim Care Respir J. 2011;20(3):238-239.
61. Jones R. Earlier detection of COPD. Prim Care Respir J. 2011;20(2):222.
62. Enright P, White P. Detecting mild COPD: don't waste resources. Prim Care Respir J. 2011;20(1):6-8.
63. Enright P. Does screening for COPD by primary care physicians have the potential to cause more harm than good? Chest. 2006;129(4):833-835.
64. Scanlon PD, Connett JE, Waller LA, et al; Lung Health Study Research Group. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study. Am J Respir Crit Care Med. 2000;161(2 pt 1): 381-390.
65. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Mölken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax. 2010; 65(8):711-718.
66. Wagena EJ, van der Meer RM, Ostelo RJ, Jacobs JE, van Schayck CP. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med. 2004;98(9):805-815.
67. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J. 2009;34(3):634-640.
68. Jiménez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001;119(5):1365-1370.
69. Jiménez Ruiz CA, Ramos Pinedo A, Cicero Guerrero A, Mayayo Ulibarri M, Cristobal Fernández M, Lopez Gonzalez G. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res. 2012;14 (9):1035-1039.
70. Clark MA, Hogan JW, Kviz FJ, Prohaska TR. Age and the role of symptomatology in readiness to quit smoking. Addict Behav. 1999;24(1):1-16.
71. Walters N, Coleman T. Comparison of the smoking behaviour and attitudes of smokers who attribute respiratory symptoms to smoking with those who do not. Br J Gen Pract. 2002;52(475): 132-134.